Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2007 Oct 10;30(Suppl 2):II-44–II-48. doi: 10.1002/clc.20230

Improving Outcomes of Percutaneous Coronary Intervention through the Application of Guidelines and Benchmarking: Reduction of Major Bleeding and Blood Transfusion as a Model

Stanley J Chetcuti 1, Paul M Grossman 1, Eva M Kline‐Rogers 1, Cecelia Montoye 2, Dean Smith 1, Mauro Moscucci 1,✉
PMCID: PMC6653616  PMID: 18228651

Abstract

Blood transfusions are a relatively common occurrence after performing any percutaneous coronary intervention (PCI). Although guidelines for blood transfusion have been previously specified, retrospective analysis of transfusion practices have suggested that these guidelines are rarely applied. We describe a model for the application of a continuous quality improvement program including benchmarking and available guidelines for blood transfusion, aimed toward reducing transfusion rates among patients undergoing PCI. Copyright © 2007 Wiley Periodicals, Inc.

Keywords: transfusion, ischemia, bleeding, quality improvement

Full Text

The Full Text of this article is available as a PDF (237.3 KB).

References

  • 1. Bovill EG, Terrin ML, Stump DC, Berke AD, Frederick M, et al.: Hemorrhagic events during therapy with recombinant tissue‐type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction, Phase II Trial. Ann Intern Med 1991; 115: 256–265. [DOI] [PubMed] [Google Scholar]
  • 2. Bovill EG, Tracy RP, Knatterud GL, Stone PH, Nasmith J, et al.: Hemorrhagic events during therapy with recombinant tissue plasminogen activator, heparin, and aspirin for unstable angina Thrombolysis in Myocardial Ischemia, phase IIIB trial. Am J Cardiol 1997; 79: 391–396. [DOI] [PubMed] [Google Scholar]
  • 3. Tcheng JE: Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: Bleeding, reversal, thrombocytopenia, and retreatment. Am Heart J 2000; 139(2): S38–S45. [DOI] [PubMed] [Google Scholar]
  • 4. Moscucci M, Rogers EK, Montoye C, Smith DE, Share D, et al.: Association of a continuous quality improvement initiative with practice and outcome variations of contemporary percutaneous coronary interventions. Circulation 2006; 113: 814–822. [DOI] [PubMed] [Google Scholar]
  • 5. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: The risk of transfusion‐transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 1996; 334: 1685–1690. [DOI] [PubMed] [Google Scholar]
  • 6. Alter HJ, Nakatsuji Y, Melpolder J, Wages J, Wesley R, et al.: The incidence of transfusion‐associated hepatitis G virus infection and its relation to liver disease. N Engl J Med 1997; 336: 747–754. [DOI] [PubMed] [Google Scholar]
  • 7. Moscucci M, Fox KA, Cannon CP, Klein W, López‐Sendón J, et al.: Predictors of major bleeding in acute coronary syndromes: The Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24: 1815–1823. [DOI] [PubMed] [Google Scholar]
  • 8. Hébert PC, Wells G, Blajchman MA, Marshall J, Martin C, et al.: A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. Transfusion Requirements in Critical Care Investigators, Canadian Critical Care Trials Group. N Engl J Med 1999; 340: 409–417. [DOI] [PubMed] [Google Scholar]
  • 9. Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, et al.: Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 2004; 292: 1555–1562. [DOI] [PubMed] [Google Scholar]
  • 10. Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, et al.: Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 2003; 92: 930–935. [DOI] [PubMed] [Google Scholar]
  • 11. Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP: Transfusion medicine. First of two parts–blood transfusion. N Engl J Med 1999; 340: 438–447. [DOI] [PubMed] [Google Scholar]
  • 12. Gong MN, Thompson BT, Williams P, Pothier L, Boyce PD, et al.: Clinical predictors of and mortality in acute respiratory distress syndrome: Potential role of red cell transfusion. Crit Care Med 2005; 33: 1191–1198. [DOI] [PubMed] [Google Scholar]
  • 13. Taylor RW, Manganaro L, O'Brien J, Trottier SJ, Parker N, et al.: Impact of allogenic packed red blood cell transfusion on nosocomial infection rates in the critically ill patient. Crit Care Med 2002; 30: 2249–2254. [DOI] [PubMed] [Google Scholar]
  • 14. Moscucci M, Mansour KA, Kent KC, Kuntz RE, Senerchia C, et al.: Peripheral vascular complications of directional coronary atherectomy and stenting: Predictors, management, and outcome. Am J Cardiol 1994; 74: 448–453. [DOI] [PubMed] [Google Scholar]
  • 15. Popma JJ, Satler LF, Pichard AD, Kent KM, Campbell A, et al.: Vascular complications after balloon and new device angioplasty. Circulation 1993; 88: 1569–1578. [DOI] [PubMed] [Google Scholar]
  • 16. Schiller GJ, Berkman SA: Hematologic aspects of renal insufficiency. Blood Rev 1989; 3: 141–146. [DOI] [PubMed] [Google Scholar]
  • 17. Follea G, Laville M, Pozet N, Dechavanne M: Pharmacokinetic studies of standard heparin and low molecular weight heparin in patients with chronic renal failure. Haemostasis 1986; 16: 147–151. [DOI] [PubMed] [Google Scholar]
  • 18. Hory B, Claudet MH, Magnette J, Bechtel P, Bayrou B: Pharmacokinetic of a very low molecular weight heparin in chronic renal failure. Thromb Res 1991; 63: 311–317. [DOI] [PubMed] [Google Scholar]
  • 19. Moscucci M, Share D, Smith D, O'Donnell MJ, Riba A, et al.: Relationship between operator volume and adverse outcome in contemporary percutaneous coronary intervention practice: An analysis of a quality‐controlled multicenter percutaneous coronary intervention clinical database. J Am Coll Cardiol 2005; 46: 625–632. [DOI] [PubMed] [Google Scholar]
  • 20. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, et al., REPLACE‐2 Investigators: Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE‐2 randomized trial. JAMA 2003; 289: 853–863. [DOI] [PubMed] [Google Scholar]
  • 21. Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, et al., ACUITY Investigators: Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355: 2203–2216. [DOI] [PubMed] [Google Scholar]
  • 22.American College of Physicians: Practice strategies for elective red blood cell transfusion. Ann Intern Med 1992; 116 403–406. [DOI] [PubMed] [Google Scholar]
  • 23. Moscucci M, Ricciardi M, Eagle KA, Kline E, Bates ER, et al.: Frequency, predictors, and appropriateness of blood transfusion after percutaneous coronary interventions. Am J Cardiol 1998; 81: 702–707. [DOI] [PubMed] [Google Scholar]
  • 24. Ghali WA, Palepu A, Paterson WG: Evaluation of red blood cell transfusion practices with the use of preset criteria. CMAJ 1994; 150: 1449–1454. [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES